Mereo BioPharma Group plc Notice of AGM (7932O)

TIDMMPH

RNS Number : 7932O

Mereo BioPharma Group plc

22 May 2018

Mereo BioPharma Group plc

("Mereo" or the "Company" or the "Group")

Notice of AGM

London, 22 May 2018 - Mereo BioPharma Group plc (AIM: MPH), a multi-asset biopharmaceutical company, today announces that the Annual General Meeting is to be held on June 21, 2018 at 11.30am (London time) at the offices of Latham & Watkins LLP, 99 Bishopsgate, London EC2M 3XF.

A copy of the Notice of Annual General Meeting is available on the Company's website: www.mereobiopharma.com.

For further information, please contact:

 
Mereo BioPharma Group plc                      [phone] 
Denise Scots-Knight, Chief Executive Officer 
Richard Jones, Chief Financial Officer 
 
Cantor Fitzgerald Europe (Nominated Adviser 
 and Broker)                                   [phone] 
Phil Davies 
Will Goode 
Rick Thompson 
 
RBC Capital Markets (Joint Broker)             [phone] 
Rupert Walford 
Laura White 
 
FTI Consulting (Public Relations Adviser)      [phone] 
Ben Atwell 
Simon Conway 
Brett Pollard 
 
Burns McClellan (US Public Relations Advisor 
 to Mereo Biopharma)                           +01 (0) 212 213 0006 
Lisa Burns 
Steven Klass 
 

About Mereo

Mereo is a multi-asset biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases. The portfolio consists of four clinical-stage product candidates, each of which were acquired from large pharmaceutical companies: BPS-804 for the treatment of osteogenesis imperfecta; AZD-9668 for the treatment of severe alpha-1 antitrypsin deficiency; BCT-197 for the treatment of acute exacerbations of chronic obstructive pulmonary disease, or AECOPD; and BGS-649 for the treatment of hypogonadotropic hypogonadism ("HH") in obese men. Each of the Company's product candidates has generated positive clinical data for Mereo's target indication or in a related indication. The Company's strategy is to selectively acquire product candidates that have already received significant investment from pharmaceutical companies and that have substantial preclinical, clinical and manufacturing data packages. Since inception the Company has commenced large, randomized, placebo-controlled Phase 2 clinical trials for three of the product candidates and announced positive top-line results from its Phase 2 clinical trial of BCT-197 as an acute therapy for patients with AECOPD in December 2017 and positive top-line data from its Phase 2b dose-ranging study with BGS-649 for the treatment of HH.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NOAFKDDPOBKDAPB

(END) Dow Jones Newswires

May 22, 2018 02:02 ET (06:02 GMT)